Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

Gastroenterology - 1 Jun 2006

Patel Raj K, Lea Nicholas C, Heneghan Michael A, Westwood Nigel B, Milojkovic Dragana, Thanigaikumar Murugaiyan, Yallop Deborah, Arya Roopen, Pagliuca Antonio, Gäken Joop, Wendon Julia, Heaton Nigel D, Mufti Ghulam J

Abstract excerpt

BACKGROUND & AIMS: Budd-Chiari Syndrome (BCS) results from obstruction to hepatic venous outflow, with myeloproliferative disorder (MPD) accounting for up to 40% of cases. A number of BCS cases labelled as "idiopathic" do not fulfill the diagnostic criteria for MPD but have features suggestive of a latent form based on hyperplastic bone marrow and erythroid progenitor cell culture; these cases may subsequently...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Budd-Chiari Syndrome
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation, Missense

Share to Probability

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Sensitivity and Specificity

Share to Statistics, Nonparametric

Source

Identifiers

PMID: 16762626
DOI: 10.1053/j.gastro.2006.04.008

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.PMID 16762626Read ↗

Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.Semantic proximity Read ↗

The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis.Semantic proximity Read ↗

The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.Semantic proximity Read ↗

Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.Semantic proximity Read ↗

Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.Semantic proximity Read ↗

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.Semantic proximity Read ↗

[Budd-Chiari syndrome and JAK2 gene mutation].Semantic proximity Read ↗

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Semantic proximity Read ↗

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.Semantic proximity Read ↗

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.Semantic proximity Read ↗

Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

Familial chronic myeloproliferative disorders: the state of the art.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.